;PMID: 9808427 ;source_file_1386.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..43] = [t:0..43] ;1)sentence:[e:48..171] = [t:48..171] ;2)section:[e:175..218] = [t:175..218] ;3)section:[e:222..323] = [t:222..323] ;4)sentence:[e:327..335] = [t:327..335] ;5)sentence:[e:336..449] = [t:336..449] ;6)sentence:[e:450..535] = [t:450..535] ;7)sentence:[e:536..635] = [t:536..635] ;8)sentence:[e:636..785] = [t:636..785] ;9)sentence:[e:787..795] = [t:787..795] ;10)sentence:[e:796..866] = [t:796..866] ;11)sentence:[e:868..945] = [t:868..945] ;12)sentence:[e:947..1037] = [t:947..1037] ;13)sentence:[e:1038..1046] = [t:1038..1046] ;14)sentence:[e:1047..1136] = [t:1047..1136] ;15)sentence:[e:1137..1241] = [t:1137..1241] ;16)sentence:[e:1242..1337] = [t:1242..1337] ;17)sentence:[e:1338..1460] = [t:1338..1460] ;18)sentence:[e:1461..1519] = [t:1461..1519] ;19)sentence:[e:1520..1639] = [t:1520..1639] ;20)sentence:[e:1640..1767] = [t:1640..1767] ;21)sentence:[e:1768..1780] = [t:1768..1780] ;22)sentence:[e:1781..1897] = [t:1781..1897] ;23)sentence:[e:1899..2087] = [t:1899..2087] ;24)sentence:[e:2088..2212] = [t:2088..2212] ;25)section:[e:2216..2260] = [t:2216..2260] ;section 0 Span:0..43 ;J Cancer Res Clin Oncol 1998;124(9):517-22 (SEC (FRAG (NNP:[0..1] J) (NNP:[2..8] Cancer) (NNP:[9..12] Res) (NNP:[13..17] Clin) (NNP:[18..23] Oncol) (.:[25..35] 1998;124-LRB-9) (-RRB-:[35..36] -RRB-) (CD:[36..40] :517) (HYPH:[40..41] -) (CD:[41..43] 22))) ;sentence 1 Span:48..171 ;Analysis of K-ras gene mutations in lung carcinomas: correlation with gender, ; histological subtypes, and clinical outcome. ;[60..65]:gene-rna:"K-ras" ;[84..99]:malignancy:"lung carcinomas" (SENT (NP-HLN (NP (NP (NN:[48..56] Analysis)) (PP (IN:[57..59] of) (NP (NN:[60..65] K-ras) (NN:[66..70] gene) (NNS:[71..80] mutations))) (PP-LOC (IN:[81..83] in) (NP (NN:[84..88] lung) (NNS:[89..99] carcinomas)))) (::[99..100] :) (NP (NP (NN:[101..112] correlation)) (PP (IN:[113..117] with) (NP (NP (NN:[118..124] gender)) (,:[124..125] ,) (NP (JJ:[127..139] histological) (NNS:[140..148] subtypes)) (,:[148..149] ,) (CC:[150..153] and) (NP (JJ:[154..162] clinical) (NN:[163..170] outcome))))) (.:[170..171] .))) ;section 2 Span:175..218 ;Wang YC, Lee HS, Chen SK, Yang SC, Chen CY. (SEC (FRAG (NNP:[175..179] Wang) (NNP:[180..182] YC) (NNP:[182..183] ,) (NNP:[184..187] Lee) (NNP:[188..190] HS) (,:[190..191] ,) (NNP:[192..196] Chen) (NNP:[197..199] SK) (,:[199..200] ,) (NNP:[201..205] Yang) (NNP:[206..208] SC) (,:[208..209] ,) (NNP:[210..214] Chen) (NNP:[215..217] CY) (.:[217..218] .))) ;section 3 Span:222..323 ;Institute of Toxicology, Chung Shan Medical and Dental College, Taichung, ;Taiwan, Republic of China. (SEC (FRAG (NNP:[222..231] Institute) (IN:[232..234] of) (NNP:[235..245] Toxicology) (,:[245..246] ,) (NNP:[247..252] Chung) (NNP:[253..257] Shan) (NNP:[258..265] Medical) (CC:[266..269] and) (NNP:[270..276] Dental) (NNP:[277..284] College) (,:[284..285] ,) (NNP:[286..294] Taichung) (,:[294..295] ,) (NNP:[297..303] Taiwan) (,:[303..304] ,) (NNP:[305..313] Republic) (IN:[314..316] of) (NNP:[317..322] China) (.:[322..323] .))) ;sentence 4 Span:327..335 ;PURPOSE: (SENT (NP (NN:[327..334] PURPOSE) (::[334..335] :))) ;sentence 5 Span:336..449 ;Lung cancer is respectively the leading and second-leading cause of cancer ;deaths among women and men in Taiwan. ;[336..347]:malignancy:"Lung cancer" (SENT (S (NP-SBJ (NN:[336..340] Lung) (NN:[341..347] cancer)) (VP (VBZ:[348..350] is) (ADVP (RB:[351..363] respectively)) (NP-PRD (NP (DT:[364..367] the) (NML (NML (VBG:[368..375] leading) (NML-1 (-NONE-:[375..375] *P*))) (CC:[376..379] and) (NML (NML (JJ:[380..386] second) (HYPH:[386..387] -) (VBG:[387..394] leading)) (NML-1 (NN:[395..400] cause))))) (PP (IN:[401..403] of) (NP (NP (NN:[405..411] cancer) (NNS:[412..418] deaths)) (PP (IN:[419..424] among) (NP (NNS:[425..430] women) (CC:[431..434] and) (NNS:[435..438] men)))))) (PP-LOC (IN:[439..441] in) (NP (NNP:[442..448] Taiwan)))) (.:[448..449] .))) ;sentence 6 Span:450..535 ;The commonest pathological type of lung carcinoma found in Taiwan is ;adenocarcinoma. ;[486..500]:malignancy:"lung carcinoma" ;[520..534]:malignancy:"adenocarcinoma" (SENT (S (NP-SBJ (NP (NP (DT:[450..453] The) (JJS:[454..463] commonest) (JJ:[464..476] pathological) (NN:[477..481] type)) (PP (IN:[482..484] of) (NP (NN:[486..490] lung) (NN:[491..500] carcinoma)))) (VP (VBN:[501..506] found) (NP (-NONE-:[506..506] *)) (PP-LOC (IN:[507..509] in) (NP (NNP:[510..516] Taiwan))))) (VP (VBZ:[517..519] is) (NP-PRD (NN:[520..534] adenocarcinoma))) (.:[534..535] .))) ;sentence 7 Span:536..635 ;and it has been documented that K-ras oncogene mutation occurs in a subset ;of lung adenocarcinoma. ;[569..574]:gene-rna:"K-ras" ;[615..634]:malignancy:"lung adenocarcinoma" (SENT (S (CC:[536..539] and) (NP-SBJ-1 (NP (PRP:[540..542] it)) (SBAR-2 (-NONE-:[542..542] *EXP*))) (VP (VBZ:[543..546] has) (VP (VBN:[547..551] been) (VP (VBN:[552..562] documented) (NP-1 (-NONE-:[562..562] *)) (SBAR-2 (IN:[564..568] that) (S (NP-SBJ (NN:[569..574] K-ras) (NN:[575..583] oncogene) (NN:[584..592] mutation)) (VP (VBZ:[593..599] occurs) (PP (IN:[600..602] in) (NP (NP (DT:[603..604] a) (NN:[605..611] subset)) (PP (IN:[612..614] of) (NP (NN:[615..619] lung) (NN:[620..634] adenocarcinoma))))))))))) (.:[634..635] .))) ;sentence 8 Span:636..785 ;We therefore investigated the mutation spectrum and clinicopathological ;significance of K-ras oncogene mutations in lung cancer patients in Taiwan. ;[726..731]:gene-rna:"K-ras" ;[754..765]:malignancy:"lung cancer" (SENT (S (NP-SBJ (PRP:[636..638] We)) (ADVP (RB:[640..649] therefore)) (VP (VBD:[650..662] investigated) (NP (NP (NP (DT:[663..666] the) (NN:[667..675] mutation) (NN:[676..684] spectrum)) (CC:[685..688] and) (NP (JJ:[689..708] clinicopathological) (NN:[710..722] significance))) (PP (IN:[723..725] of) (NP (NN:[726..731] K-ras) (NN:[732..740] oncogene) (NNS:[741..750] mutations))) (PP-LOC (IN:[751..753] in) (NP (NN:[754..758] lung) (NN:[759..765] cancer) (NNS:[766..774] patients)))) (PP-LOC (IN:[775..777] in) (NP (NNP:[778..784] Taiwan)))) (.:[784..785] .))) ;sentence 9 Span:787..795 ;METHODS: (SENT (NP (NNS:[787..794] METHODS) (::[794..795] :))) ;sentence 10 Span:796..866 ;The lung tumors were surgically resected from 84 lung cancer patients. ;[800..811]:malignancy:"lung tumors" ;[845..856]:malignancy:"lung cancer" (SENT (S (NP-SBJ-1 (DT:[796..799] The) (NN:[800..804] lung) (NNS:[805..811] tumors)) (VP (VBD:[812..816] were) (ADVP-MNR (RB:[817..827] surgically)) (VP (VBN:[828..836] resected) (NP-1 (-NONE-:[836..836] *)) (PP (IN:[837..841] from) (NP (CD:[842..844] 84) (NML (NN:[845..849] lung) (NN:[850..856] cancer)) (NNS:[857..865] patients))))) (.:[865..866] .))) ;sentence 11 Span:868..945 ;DNA was isolated and the mutation spectrum was examined by direct ;sequencing. (SENT (S (S (NP-SBJ-2 (NN:[868..871] DNA)) (VP (VBD:[872..875] was) (VP (VBN:[876..884] isolated) (NP-2 (-NONE-:[884..884] *))))) (CC:[885..888] and) (S (NP-SBJ-1 (DT:[889..892] the) (NN:[893..901] mutation) (NN:[902..910] spectrum)) (VP (VBD:[911..914] was) (VP (VBN:[915..923] examined) (NP-1 (-NONE-:[923..923] *)) (PP-MNR (IN:[924..926] by) (NP (JJ:[927..933] direct) (NN:[934..944] sequencing)))))) (.:[944..945] .))) ;sentence 12 Span:947..1037 ;These data were also correlated with the clinicopathological characteristics ;of patients. (SENT (S (NP-SBJ-1 (DT:[947..952] These) (NNS:[953..957] data)) (VP (VBD:[958..962] were) (ADVP (RB:[963..967] also)) (VP (VBN:[968..978] correlated) (NP-1 (-NONE-:[978..978] *)) (PP-CLR (IN:[979..983] with) (NP (NP (DT:[984..987] the) (JJ:[988..1007] clinicopathological) (NNS:[1008..1023] characteristics)) (PP (IN:[1024..1026] of) (NP (NNS:[1028..1036] patients))))))) (.:[1036..1037] .))) ;sentence 13 Span:1038..1046 ;RESULTS: (SENT (NP (NNS:[1038..1045] RESULTS) (::[1045..1046] :))) ;sentence 14 Span:1047..1136 ;K-ras gene mutations were detected in 5 cases among the 84 patients ;investigated (6.0%). ;[1047..1052]:gene-rna:"K-ras" (SENT (S (NP-SBJ-1 (NN:[1047..1052] K-ras) (NN:[1053..1057] gene) (NNS:[1058..1067] mutations)) (VP (VBD:[1068..1072] were) (VP (VBN:[1073..1081] detected) (NP-1 (-NONE-:[1081..1081] *)) (PP (IN:[1082..1084] in) (NP (NP (CD:[1085..1086] 5) (NNS:[1087..1092] cases)) (PP (IN:[1093..1098] among) (NP (NP (DT:[1099..1102] the) (CD:[1103..1105] 84) (NNS:[1107..1115] patients)) (VP (VBN:[1116..1128] investigated) (NP (-NONE-:[1128..1128] *))))))) (PRN (-LRB-:[1129..1130] -LRB-) (NP (CD:[1130..1133] 6.0) (NN:[1133..1134] %)) (-RRB-:[1134..1135] -RRB-)))) (.:[1135..1136] .))) ;sentence 15 Span:1137..1241 ;The majority of mutations occurred in exon 1 (80%, 4 of 5) and were located ;mainly in codons 12 and 13. ;[1153..1162]:variation-event:"mutations" ;[1175..1181]:variation-location:"exon 1" ;[1224..1233]:variation-location:"codons 12" ;[1224..1230]...[1238..1240]:variation-location:"codons"..."13" (SENT (S (NP-SBJ-2 (NP (DT:[1137..1140] The) (NN:[1141..1149] majority)) (PP (IN:[1150..1152] of) (NP (NNS:[1153..1162] mutations)))) (VP (VP (VBD:[1163..1171] occurred) (PP-LOC (IN:[1172..1174] in) (NP (NN:[1175..1179] exon) (CD:[1180..1181] 1))) (PRN (-LRB-:[1182..1183] -LRB-) (FRAG (NP (CD:[1183..1185] 80) (NN:[1185..1186] %)) (,:[1186..1187] ,) (NP (NP (CD:[1189..1190] 4)) (PP (IN:[1191..1193] of) (NP (CD:[1194..1195] 5))))) (-RRB-:[1195..1196] -RRB-))) (CC:[1197..1200] and) (VP (VBD:[1201..1205] were) (VP (VBN:[1206..1213] located) (NP-2 (-NONE-:[1213..1213] *)) (ADVP (RB:[1214..1220] mainly)) (PP-LOC (IN:[1221..1223] in) (NP (NP (NML-1 (NNS:[1224..1230] codons)) (CD:[1231..1233] 12)) (CC:[1234..1237] and) (NP (NML-1 (-NONE-:[1237..1237] *P*)) (CD:[1238..1240] 13))))))) (.:[1240..1241] .))) ;sentence 16 Span:1242..1337 ;Two patients had G x C --> T x A transversions and 2 patients had G x C --> ;A x T transitions. ;[1259..1260]:variation-state-original:"G" ;[1263..1264]:variation-state-original:"C" ;[1270..1271]:variation-state-altered:"T" ;[1274..1275]:variation-state-altered:"A" ;[1276..1289]:variation-type:"transversions" ;[1309..1310]:variation-state-original:"G" ;[1313..1314]:variation-state-original:"C" ;[1319..1320]:variation-state-altered:"A" ;[1323..1324]:variation-state-altered:"T" ;[1325..1336]:variation-type:"transitions" (SENT (S (S (NP-SBJ (CD:[1242..1245] Two) (NNS:[1246..1254] patients)) (VP (VBD:[1255..1258] had) (NP (NML (NML (NN:[1259..1260] G) (SYM:[1261..1262] x) (NN:[1263..1264] C)) (PP (SYM:[1265..1268] -->) (NML (NN:[1270..1271] T) (SYM:[1272..1273] x) (NN:[1274..1275] A)))) (NNS:[1276..1289] transversions)))) (CC:[1290..1293] and) (S (NP-SBJ (CD:[1294..1295] 2) (NNS:[1296..1304] patients)) (VP (VBD:[1305..1308] had) (NP (NML (NML (NN:[1309..1310] G) (SYM:[1311..1312] x) (NN:[1313..1314] C)) (PP (SYM:[1315..1318] -->) (NML (NN:[1319..1320] A) (SYM:[1321..1322] x) (NN:[1323..1324] T)))) (NNS:[1325..1336] transitions)))) (.:[1336..1337] .))) ;sentence 17 Span:1338..1460 ;Notably, 1 patient had a G x C base-pair deletion from the contiguous G x C ;base pairs located between codons 68 and 69. ;[1364..1365]:variation-state-original:"G" ;[1368..1369]:variation-state-original:"C" ;[1370..1388]:variation-type:"base-pair deletion" ;[1435..1459]:variation-location:"between codons 68 and 69" (SENT (S (ADVP (RB:[1338..1345] Notably)) (,:[1345..1346] ,) (NP-SBJ (CD:[1347..1348] 1) (NN:[1350..1357] patient)) (VP (VBD:[1358..1361] had) (NP (NP (DT:[1362..1363] a) (NML (NML (NN:[1364..1365] G) (SYM:[1366..1367] x) (NN:[1368..1369] C)) (NML (NN:[1370..1374] base) (HYPH:[1374..1375] -) (NN:[1375..1379] pair))) (NN:[1380..1388] deletion)) (PP (IN:[1389..1393] from) (NP (NP (DT:[1394..1397] the) (JJ:[1398..1408] contiguous) (NML (NN:[1409..1410] G) (SYM:[1411..1412] x) (NN:[1413..1414] C)) (NN:[1415..1419] base) (NNS:[1420..1425] pairs)) (VP (VBN:[1427..1434] located) (NP (-NONE-:[1434..1434] *)) (PP-LOC (IN:[1435..1442] between) (NP (NP (NML-1 (NNS:[1443..1449] codons)) (CD:[1450..1452] 68)) (CC:[1453..1456] and) (NP (NML-1 (-NONE-:[1456..1456] *P*)) (CD:[1457..1459] 69))))))))) (.:[1459..1460] .))) ;sentence 18 Span:1461..1519 ;All mutations occurred in male patients who were smokers. (SENT (S (NP-SBJ (DT:[1461..1464] All) (NNS:[1465..1474] mutations)) (VP (VBD:[1475..1483] occurred) (PP-LOC (IN:[1484..1486] in) (NP (NP (JJ:[1487..1491] male) (NNS:[1492..1500] patients)) (SBAR (WHNP-1 (WP:[1501..1504] who)) (S (NP-SBJ-1 (-NONE-:[1504..1504] *T*)) (VP (VBD:[1506..1510] were) (NP-PRD (NNS:[1511..1518] smokers)))))))) (.:[1518..1519] .))) ;sentence 19 Span:1520..1639 ;The incidences of K-ras gene mutation among male and female patients with ;adenocarcinoma were 13% and 0% respectively. ;[1538..1543]:gene-rna:"K-ras" ;[1595..1609]:malignancy:"adenocarcinoma" (SENT (S (NP-SBJ (NP (DT:[1520..1523] The) (NNS:[1524..1534] incidences)) (PP (IN:[1535..1537] of) (NP (NN:[1538..1543] K-ras) (NN:[1544..1548] gene) (NN:[1549..1557] mutation))) (PP (IN:[1558..1563] among) (NP (NP (NP (JJ:[1564..1568] male) (NML-1 (-NONE-:[1568..1568] *P*))) (CC:[1569..1572] and) (NP (JJ:[1573..1579] female) (NML-1 (NNS:[1581..1589] patients)))) (PP (IN:[1590..1594] with) (NP (NN:[1595..1609] adenocarcinoma)))))) (VP (VBD:[1610..1614] were) (NP-PRD (NP (CD:[1615..1617] 13) (NN:[1617..1618] %)) (CC:[1619..1622] and) (NP (CD:[1623..1624] 0) (NN:[1624..1625] %))) (ADVP (RB:[1626..1638] respectively))) (.:[1638..1639] .))) ;sentence 20 Span:1640..1767 ;Patients with K-ras gene mutation survived for shorter periods than those ;without mutations (P = 0.08, by the log-rank test). ;[1654..1659]:gene-rna:"K-ras" (SENT (S (NP-SBJ (NP (NNS:[1640..1648] Patients)) (PP (IN:[1649..1653] with) (NP (NN:[1654..1659] K-ras) (NN:[1661..1665] gene) (NN:[1666..1674] mutation)))) (VP (VBD:[1675..1683] survived) (PP-TMP (IN:[1684..1687] for) (NP (NP (JJR:[1688..1695] shorter) (NNS:[1696..1703] periods)) (PP (IN:[1704..1708] than) (NP (NP (DT:[1709..1714] those)) (PP (IN:[1715..1722] without) (NP (NNS:[1723..1732] mutations))))))) (PRN (-LRB-:[1733..1734] -LRB-) (FRAG (S (NP-SBJ (NN:[1734..1735] P)) (VP (SYM:[1736..1737] =) (NP (CD:[1739..1743] 0.08)))) (,:[1743..1744] ,) (PP (IN:[1745..1747] by) (NP (DT:[1748..1751] the) (NML (NN:[1752..1755] log) (HYPH:[1755..1756] -) (NN:[1756..1760] rank)) (NN:[1761..1765] test)))))) (-RRB-:[1765..1766] -RRB-) (.:[1766..1767] .))) ;sentence 21 Span:1768..1780 ;CONCLUSIONS: (SENT (NP (NNS:[1768..1779] CONCLUSIONS) (::[1779..1780] :))) ;sentence 22 Span:1781..1897 ;The incidence of K-ras gene mutations for male and female patients with ;adenocarcinoma was 13% and 0% respectively. ;[1798..1803]:gene-rna:"K-ras" ;[1854..1868]:malignancy:"adenocarcinoma" (SENT (S (NP-SBJ (NP (DT:[1781..1784] The) (NN:[1785..1794] incidence)) (PP (IN:[1795..1797] of) (NP (NN:[1798..1803] K-ras) (NN:[1804..1808] gene) (NNS:[1809..1818] mutations))) (PP (IN:[1820..1823] for) (NP (NP (NP (JJ:[1824..1828] male) (NML-1 (-NONE-:[1828..1828] *P*))) (CC:[1829..1832] and) (NP (JJ:[1833..1839] female) (NML-1 (NNS:[1840..1848] patients)))) (PP (IN:[1849..1853] with) (NP (NN:[1854..1868] adenocarcinoma)))))) (VP (VBD:[1869..1872] was) (NP-PRD (NP (CD:[1873..1875] 13) (NN:[1875..1876] %)) (CC:[1877..1880] and) (NP (CD:[1881..1882] 0) (NN:[1882..1883] %))) (ADVP (RB:[1884..1896] respectively))) (.:[1896..1897] .))) ;sentence 23 Span:1899..2087 ;Thus, the role of K-ras in the development of lung adenocarcinoma among ;Chinese men who are predominantly smokers is not significantly different ;from that in other populations worldwide. ;[1917..1922]:gene-rna:"K-ras" ;[1945..1964]:malignancy:"lung adenocarcinoma" (SENT (S (ADVP (RB:[1899..1903] Thus)) (,:[1903..1904] ,) (NP-SBJ (NP (DT:[1905..1908] the) (NN:[1909..1913] role)) (PP (IN:[1914..1916] of) (NP (NN:[1917..1922] K-ras))) (PP (IN:[1923..1925] in) (NP (NP (DT:[1926..1929] the) (NN:[1930..1941] development)) (PP (IN:[1942..1944] of) (NP (NN:[1945..1949] lung) (NN:[1950..1964] adenocarcinoma))) (PP (IN:[1965..1970] among) (NP (NP (JJ:[1971..1978] Chinese) (NNS:[1980..1983] men)) (SBAR (WHNP-1 (WP:[1984..1987] who)) (S (NP-SBJ-1 (-NONE-:[1987..1987] *T*)) (VP (VBP:[1988..1991] are) (ADVP (RB:[1992..2005] predominantly)) (NP-PRD (NNS:[2006..2013] smokers)))))))))) (VP (VBZ:[2014..2016] is) (RB:[2017..2020] not) (ADJP-PRD (RB:[2021..2034] significantly) (JJ:[2035..2044] different) (PP (IN:[2045..2049] from) (NP (NP (DT:[2050..2054] that)) (PP (IN:[2055..2057] in) (NP (JJ:[2059..2064] other) (NNS:[2065..2076] populations) (RB:[2077..2086] worldwide))))))) (.:[2086..2087] .))) ;sentence 24 Span:2088..2212 ;However, K-ras mutations may not be associated with adenocarcinoma among ;women in Taiwan, who are virtually all nonsmokers. ;[2097..2102]:gene-rna:"K-ras" ;[2141..2155]:malignancy:"adenocarcinoma" (SENT (S (ADVP (RB:[2088..2095] However)) (,:[2095..2096] ,) (NP-SBJ-2 (NN:[2097..2102] K-ras) (NNS:[2103..2112] mutations)) (VP (MD:[2113..2116] may) (RB:[2117..2120] not) (VP (VB:[2121..2123] be) (VP (VBN:[2124..2134] associated) (NP-2 (-NONE-:[2134..2134] *)) (PP-CLR (IN:[2135..2139] with) (NP (NP (NN:[2141..2155] adenocarcinoma)) (PP (IN:[2156..2161] among) (NP (NP (NP (NNS:[2162..2167] women)) (PP-LOC (IN:[2168..2170] in) (NP (NNP:[2171..2177] Taiwan)))) (,:[2177..2178] ,) (SBAR (WHNP-1 (WP:[2179..2182] who)) (S (NP-SBJ-1 (-NONE-:[2182..2182] *T*)) (VP (VBP:[2183..2186] are) (NP-PRD (QP (RB:[2187..2196] virtually) (DT:[2197..2200] all)) (NNS:[2201..2211] nonsmokers)))))))))))) (.:[2211..2212] .))) ;section 25 Span:2216..2260 ;PMID: 9808427 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[2216..2220] PMID) (::[2220..2221] :) (CD:[2222..2229] 9808427) (IN:[2230..2231] -LSB-) (NNP:[2231..2237] PubMed) (HYPH:[2238..2239] -) (JJ:[2240..2247] indexed) (IN:[2248..2251] for) (NNP:[2252..2260] MEDLINE-RSB-)))